C1

(L) of 16 residues (SEQ. ID. No. 5), a heavy chain variable region (V_H) of 122 amino acids, a connector segment (C) of 5 amino acids (KASGG) (SEQ. ID. No. 9), and the PE38 mutant, comprising 347 amino acids ("Toxin").

IN THE CLAIMS

Cancel claims 19-28, without prejudice. Amend claims 31-33 as follows:

Claim 31 (amended). A recombinant immunotoxin polypeptide and the pharmaceutically acceptable salts thereof, wherein the polypeptide comprises the polypeptide encoded by a nucleotide sequence which hybridizes to the nucleotide sequence of claim 30 (SEQ. ID. No. 2) under stringent hybridization conditions.

C2

Claim 32 (amended). A recombinant immunotoxin polypeptide and the pharmaceutically acceptable salts thereof, wherein the polypeptide comprises the polypeptide encoded by any nucleotide sequence which hybridizes to said nucleotide sequence of claim 31 under stringent hybridization conditions.

Claim 33 (amended). A recombinant immunotoxin polypeptide and pharmaceutically acceptable salts thereof according to claim 2, wherein the CD3-binding domain comprises the FV region, or a CD3-binding fragment thereof of an antibody selected from: monoclonal antibody UCHT-1, an antibody having a variable region which is at least 90% identical to the variable region of UCHT-1 and is at least about 90% as effective on a molar basis in competing with UCHT-1 for binding to human CD3 antigen and having at least one sequence segment of at least five amino acids of human origin.

Appendix A contains a marked-up version of the amended claims and amended part of the specification indicating the changes.